Skip to main navigation Skip to search Skip to main content

Clinical applicability of Quantiferon-TB-Gold testing in psoriasis patients during long-term anti-TNF-alpha treatment: a prospective, observational study

  • Simone Garcovich
  • , Alberto Ruggeri
  • , Magda D'Agostino
  • , Fausta Ardito
  • , Clara De Simone
  • , Giovanni Delogu
  • , G. Fadda

Research output: Contribution to journalArticle

Abstract

Psoriasis patients who are treated with tumour necrosis factor (TNF)-alpha antagonists are at increased risk of reactivation of latent tuberculosis infection (LTBI) and should be adequately screened and monitored during active treatment.
Original languageEnglish
Pages (from-to)1572-1576
Number of pages5
JournalJournal of the European Academy of Dermatology and Venereology
Volume26
DOIs
Publication statusPublished - 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • tbc

Fingerprint

Dive into the research topics of 'Clinical applicability of Quantiferon-TB-Gold testing in psoriasis patients during long-term anti-TNF-alpha treatment: a prospective, observational study'. Together they form a unique fingerprint.

Cite this